| Jun 18 |
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
|
| Jun 12 |
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
|
| May 30 |
Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript
|
| May 30 |
Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
|
| May 29 |
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
|
| May 28 |
Cellectis GAAP EPS of -$0.15 beats by $0.16, revenue of $6.5M beats by $3.09M
|
| May 28 |
Cellectis Reports Financial Results for First Quarter 2024
|
